CareDx announces AlloSeq cfDNA study data published in Transplant International

CareDx (CDNA) announced findings published in Transplant International that show the performance of AlloSeq cfDNA in detecting allograft rejection was consistent with its AlloSure lab developed test. The multicenter prospective study included 580 kidney transplant patients from three referral transplant centers in Europe. The study showed that AlloSeq cfDNA was highly accurate in detecting allograft rejection in kidney transplant patients, with a significant difference between rejection and non-rejection and an AUC of 0.758. Consistency in performance between AlloSeq cfDNA and AlloSure Kidney dd-cfDNA was confirmed across clinical scenarios including post-transplant timepoints, allograft stability, and allograft rejection subcategories; each compared to biopsy proven rejection.